Peripersonal Space Representation in Upper Limb Segmental Exclusion

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUnion de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est

About this trial

This study aims to evaluate the representation of action peripersonal space (PPS) in subjects suffering from unilateral segmental exclusion syndrome of the upper limb compared to healthy control subjects. Segmental exclusion is defined by non-use or under-use of a limb segment without central nervous system damage. The study hypothesizes that this syndrome leads to a modification (shrinkage) of the PPS representation. Participants will perform reachability judgments in a Virtual Reality (VR) environment.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age ≥ 18 years.

Presenting unilateral exclusion symptom of the upper limb or part of the hand evolving for > 3 months.

No contraindication to force work in daily activities.

For patients with finger exclusion: at least 2 perturbed items related to exclusion on tests 3 and 4 of the "Bilan 400 points".

Disqualifiers

Visual impairments.

Central neurological pathology.

Unstabilized psychiatric pathology.

Communication or comprehension difficulties.

Trial population

he study population consists of two groups recruited at the Institut Régional de Réadaptation (Centre Louis Pierquin, UGECAM Nord-Est) in Nancy, France. Patients with Exclusion: Participants are selected from patients receiving routine care (full hospitalization or day hospital) at the center. They are identified based on a functional assessment ("Bilan 400 points") showing specific impairments related to unilateral upper limb exclusion evolving for more than 3 months. Healthy Controls: Asymptomatic volunteers are recruited through the social or family network of the investigators and current participants, as well as via posters displayed in the UGECAM centers.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Reachability Judgment Task in VR.

    Behavioral

    Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Patients with Exclusion1 intervention
Group B: Healthy Controls1 intervention

Trial outcomes

Primary outcomes

1

Judgment Error of Reachability

The Judgment Error of Reachability is a single composite metric calculated as: ((DMA-p - DMA-r) / DMA-r) × 100, expressed as a percentage (%). Both DMA-p (Perceived Maximum Reachable Distance) and DMA-r (Real Maximum Reachable Distance) are measured in centimeters, and their ratio yields a single dimensionless percentage score.

Time frame
Day 1 (During the 40-minute VR assessment)

Secondary outcomes

1

Body Perception Disturbance Score

Assessed using the Bath CRPS Body Perception Disturbance Scale (French version). Scores range from 0 to 57, with higher scores indicating greater disturbance.

Time frame
Day 1 (Before VR task)
2

Functional Impairment Score (400-Point Hand Assessment)

Evaluated using the 400-Point Hand Assessment, which measures functional hand use. The score ranges from 0 to 400, where higher scores indicate better functional performance (better outcome).

Time frame
Day 1
3

Anxiety and Depression Score (HAD)

Hospital Anxiety and Depression Scale. Scores range from 0 to 21 for each dimension (Anxiety and Depression).

Time frame
Day 1
4

Kinesiophobia Score (Tampa Scale)

Tampa Scale for Kinesiophobia (TSK). Assesses fear of movement. Scores range to 68; \>40 indicates significant kinesiophobia.

Time frame
Day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.